SCHEMBL1309948

SCHEMBL1309948

O=C(O)c1cc(Cl)ccc1NC(=O)c1cccc(F)c1F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C4 P17516 1/20 0.60
AKR1C3 P42330 1/20 0.60
AKR1C2 P52895 1/20 0.60
AKR1C1 Q04828 1/20 0.60
SERPINE1 P05121 7/20 0.57
KDM4E B2RXH2 1/20 0.55
HSD17B10 Q99714 1/20 0.55
KCNMA1 Q12791 1/20 0.54
RAB9A P51151 2/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
NPC1 O15118 1/20 0.53
HPGD P15428 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
LMNA P02545 2/20 0.52
PPARG P37231 1/20 0.52
PPARA Q07869 1/20 0.52
ALDH1A1 P00352 1/20 0.52
MAPT P10636 1/20 0.52
CA12 O43570 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1307881 0.89 KCNMA1 (0.68) AKR1C4AKR1C3AKR1C2AKR1C1SERPINE1
SCHEMBL14855607 0.86 KCNMA1 (0.65) AKR1C4AKR1C3AKR1C2AKR1C1SERPINE1
SCHEMBL1308873 0.85 PTPRC (0.56) AKR1C4AKR1C3AKR1C2AKR1C1MEN1
SCHEMBL1307653 0.84 AKR1C2 (0.60) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL14855933 0.84 KCNMA1 (0.65) AKR1C4AKR1C3AKR1C2AKR1C1SERPINE1
SCHEMBL1308425 0.81 TAS1R3 (0.63) AKR1C4AKR1C3AKR1C2AKR1C1SERPINE1
SCHEMBL1308248 0.80 TAS1R3 (0.65) AKR1C4AKR1C3AKR1C2AKR1C1SERPINE1
SCHEMBL1309941 0.79 SERPINE1 (0.65) AKR1C4AKR1C3AKR1C2AKR1C1SERPINE1
SCHEMBL1308410 0.78 GFER (0.76) AKR1C4AKR1C3AKR1C2AKR1C1SERPINE1
SCHEMBL5950326 0.78 GRIK1 (0.80) SERPINE1KDM4EHSD17B10RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2009-02-12 US claimed
US-8053454-B2 Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2011-11-08 US disclosed
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2009-02-12 US disclosed
WO-2004022525-A1 AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 PIM1, PIM3, PIM2 AKR1C4 2250/4885AKR1C3 2015/4885AKR1C2 2289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.